NCOA3 and breast carcinoma: As shown in the present study, SI-2 treatment also reduced the progression of E0771 breast cancer in immune-intact syngeneic female mice by reducing SRC-3 levels in vitro and in vivo because SRC-3 plays an essential role in E0771 breast cancer progression [31].